secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcturus Therapeutics Holdings Inc. (ARCT)
CIK:        0001768224
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193805-25-001555
Event type: earnings
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud

Arcturus Therapeutics Reports Q3 2025 Net Loss of $13.5M, Progresses ARCT-032 and ARCT-810 Programs
--------------------------------------------------------------------------------

- Q3 2025 revenue was $17.2M, down $24.5M from prior year; net loss $13.5M ($0.49 per share) vs $6.9M loss in Q3 2024.
- ARCT-032 Phase 2 interim data: inhaled 10mg daily over 28 days well tolerated; mucus burden reduced in 4 of 6 Class I CF adults per HRCT scans.
- Company plans a 12-week safety and efficacy study of ARCT-032 in up to 20 CF participants starting H1 2026.
- FDA changes delayed U.S. BLA filing for KOSTAIVE indefinitely; additional cost reductions planned in Q4 2025 to extend cash runway into 2028.
- ARCT-2304 pandemic flu vaccine candidate induced humoral immune response after single dose at all tested levels, supporting further development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525001555/0001193805-25-001555-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1768224/000119380525001555/e664953_8k-arct.htm
  HTML page:      https://secwatch.observer/filing/0001193805-25-001555

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer